Skip to main content
PMC home page
CMAJ : Canadian Medical Association Journal logoLink to CMAJ : Canadian Medical Association Journal
. 1993 Dec 15;149(12):1807–1808.

High-density-lipoprotein cholesterol and atherosclerosis.

D S Ng 1, R A Hegele 1
PMCID: PMC1485760  PMID: 8261351

Full text

PDF
1807

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Badimon J. J., Badimon L., Galvez A., Dische R., Fuster V. High density lipoprotein plasma fractions inhibit aortic fatty streaks in cholesterol-fed rabbits. Lab Invest. 1989 Mar;60(3):455–461. [PubMed] [Google Scholar]
  2. Cheung M. C., Albers J. J. Characterization of lipoprotein particles isolated by immunoaffinity chromatography. Particles containing A-I and A-II and particles containing A-I but no A-II. J Biol Chem. 1984 Oct 10;259(19):12201–12209. [PubMed] [Google Scholar]
  3. Frohlich J., Westerlund J., Sparks D., Pritchard P. H. Familial hypoalphalipoproteinemias. Clin Invest Med. 1990 Aug;13(4):202–210. [PubMed] [Google Scholar]
  4. Gordon D. J., Probstfield J. L., Garrison R. J., Neaton J. D., Castelli W. P., Knoke J. D., Jacobs D. R., Jr, Bangdiwala S., Tyroler H. A. High-density lipoprotein cholesterol and cardiovascular disease. Four prospective American studies. Circulation. 1989 Jan;79(1):8–15. doi: 10.1161/01.cir.79.1.8. [DOI] [PubMed] [Google Scholar]
  5. Hamsten A., Walldius G., Dahlén G., Johansson B., De Faire U. Serum lipoproteins and apolipoproteins in young male survivors of myocardial infarction. Atherosclerosis. 1986 Feb;59(2):223–235. doi: 10.1016/0021-9150(86)90051-1. [DOI] [PubMed] [Google Scholar]
  6. Horowitz B. S., Goldberg I. J., Merab J., Vanni T. M., Ramakrishnan R., Ginsberg H. N. Increased plasma and renal clearance of an exchangeable pool of apolipoprotein A-I in subjects with low levels of high density lipoprotein cholesterol. J Clin Invest. 1993 Apr;91(4):1743–1752. doi: 10.1172/JCI116384. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Miller G. J., Miller N. E. Plasma-high-density-lipoprotein concentration and development of ischaemic heart-disease. Lancet. 1975 Jan 4;1(7897):16–19. doi: 10.1016/s0140-6736(75)92376-4. [DOI] [PubMed] [Google Scholar]
  8. Miller N. E. Associations of high-density lipoprotein subclasses and apolipoproteins with ischemic heart disease and coronary atherosclerosis. Am Heart J. 1987 Feb;113(2 Pt 2):589–597. doi: 10.1016/0002-8703(87)90638-7. [DOI] [PubMed] [Google Scholar]
  9. Puchois P., Kandoussi A., Fievet P., Fourrier J. L., Bertrand M., Koren E., Fruchart J. C. Apolipoprotein A-I containing lipoproteins in coronary artery disease. Atherosclerosis. 1987 Nov;68(1-2):35–40. doi: 10.1016/0021-9150(87)90091-8. [DOI] [PubMed] [Google Scholar]
  10. Rader D. J., Castro G., Zech L. A., Fruchart J. C., Brewer H. B., Jr In vivo metabolism of apolipoprotein A-I on high density lipoprotein particles LpA-I and LpA-I,A-II. J Lipid Res. 1991 Nov;32(11):1849–1859. [PubMed] [Google Scholar]
  11. Rubin E. M., Krauss R. M., Spangler E. A., Verstuyft J. G., Clift S. M. Inhibition of early atherogenesis in transgenic mice by human apolipoprotein AI. Nature. 1991 Sep 19;353(6341):265–267. doi: 10.1038/353265a0. [DOI] [PubMed] [Google Scholar]

Articles from CMAJ: Canadian Medical Association Journal are provided here courtesy of Canadian Medical Association

RESOURCES